| Gene symbol | APOB | Synonyms | FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48 | Type of gene | protein-coding |
| Chromosome | 2 | Map location | 2p24.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | apolipoprotein B | ||||
| GTO ID | GTC1354 |
| Trial ID | NCT01133366 |
| Disease | Familial Hypercholesterolemia |
| Altered gene | APOB |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 301012|mipomersen sodium|Kynamro |
| Co-treatment | warfarin sodium |
| Location approved | US, Mexico, Argentina, South Korea |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Drug-Drug Interaction Study to Assess the Effects of Multiple Doses of Mipomersen (200 mg SC) on Single-Dose Warfarin (25 mg) Pharmacodynamics and Pharmacokinetics in Healthy Adult Subjects |
| Year | 2010 |
| Country | United States |
| Company sponsor | Kastle Therapeutics, LLC |
| Other ID(s) | MIPO2900509 |
| Vector information | |||
|
|||
| Cohort1: warfarin | |||||||
|
|||||||
| Cohort2: warfarin_mipomersen | |||||||
|
|||||||